Affordable Access

Publisher Website

Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).

  • Thaçi, D1
  • Pinter, A2
  • Sebastian, M3
  • Termeer, C4, 5
  • Sticherling, M6
  • Gerdes, S7
  • Wegner, S8
  • Krampe, S8
  • Bartz, H8
  • Rausch, C8
  • Mensch, A8
  • Eyerich, K9
  • 1 Institute and Comprehensive Centre for Inflammation Medicine, University of Lübeck, Lübeck, Germany. , (Germany)
  • 2 Department of Dermatology, Venereology and Allergology, University Hospital of Frankfurt am Main, Frankfurt am Main, Germany. , (Germany)
  • 3 Dermatological Practice Dr. med. Michael Sebastian, Mahlow, Germany. , (Germany)
  • 4 Dermatological Practice Prof. Dr. med. Christian Termeer, Stuttgart, Germany. , (Germany)
  • 5 Department of Dermatology, University of Freiburg, Freiburg, Germany. , (Germany)
  • 6 Department of Dermatology, University Hospital of Erlangen, Erlangen, Germany. , (Germany)
  • 7 Psoriasis-Center, Department of Dermatology, Venerology and Allergology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. , (Germany)
  • 8 Janssen-Cilag GmbH, Neuss, Germany. , (Germany)
  • 9 Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany. , (Germany)
Published Article
British Journal of Dermatology
Wiley (Blackwell Publishing)
Publication Date
Aug 01, 2020
DOI: 10.1111/bjd.18696
PMID: 31705526


Guselkumab, a fully human interleukin-23 antibody, is approved for systemic treatment of patients with moderate-to-severe plaque psoriasis. To compare the efficacy and safety of guselkumab with those of fumaric acid esters (FAE) in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment. Eligible patients were randomized to this multicentre, randomized, open-label, assessor-blinded, active-comparator-controlled phase IIIb study to receive guselkumab 100 mg by subcutaneous injection or oral FAE according to local label guidelines. Through week 24, 56 of 60 patients completed guselkumab treatment and 36 of 59 completed FAE treatment. The primary endpoint (proportion of patients with ≥ 90% improvement from their baseline Psoriasis Area and Severity Index; PASI 90 response) was achieved by significantly more patients receiving guselkumab than FAE at week 24 (82% vs. 14%, P < 0·001). Analysis of the major secondary endpoints confirmed a statistically significant difference between the treatments with regards to PASI 75 response (90% vs. 27%, P < 0·001) and Dermatology Life Quality Index score of 0 or 1 (no effect at all on the patient's quality of life; 62% vs. 17%, P < 0·001). More patients in the guselkumab group achieved completely clear skin (PASI 100 response) than in the FAE group (32% vs. 3%, P < 0·001). The incidence of adverse events was lower with guselkumab than with FAE (73% vs. 98%). Overall, 28% of patients on FAE discontinued due to an adverse event, compared with none receiving guselkumab. No new safety findings were observed for guselkumab. Guselkumab demonstrated superiority over FAE in systemic-treatment-naive patients with moderate-to-severe plaque psoriasis through 24 weeks. © 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

Report this publication


Seen <100 times